MBX Biosciences launches Phase 2 drug trial

June 19, 2024

MBX Biosciences Phase 2 drug trial is now open.
The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.

To learn more about their drug and the science behind it go to MBX 2109 link

To register to participate in their phase 2 trial or find out more about the criteria to participate go to Clinical Trials MBX

 

 

 

Back to News